. 2016 Aug 18;144(16):3365–3375. doi: 10.1017/S0950268816001849

Table 3.

Studies in different regions with different endemicity showing seroprotection after infant vaccination programme, the breakthrough infections (HBsAg, anti-HBc) and anamnestic response to a booster dose

Duration of follow-up, years	No. of subjects	Country	No. of doses and schedule (months)	Seroprotection^* (%)	HBsAg(+)	Anti-HBc(+)	Anamnestic response^†	Ref., year of publication
10	606 vaccinated	Germany	3 doses:	78%	NT	NT	97·2%. After 1 booster dose at 10 years if anti-Hbs <10 mIU/ml	[45], 2012
10	606 vaccinated	Germany	0, 1, 6	78%	NT	NT		[45], 2012
10	1212 vaccinated	Italy	3 doses:	64%	0	1%	97%. After 1 booster dose at 10 years if anti-Hbs <10 mIU/ml	[28], 2005
10	1212 vaccinated	Italy	3, 5, 11	64%	0	1%		[28], 2005
10	663 vaccinated	Canada	3 doses:	86·4%	NT	NT	100%. After 1 booster dose at 10 years if anti-Hbs <10 mIU/ml	[46], 2013
10	663 vaccinated	Canada	birth, 1, 6	86·4%	NT	NT		[46], 2013
10	146 vaccinated	Iran	3 doses:	47·9%	0	7·5%	95%. After1 booster dose at 10 years if anti-Hbs <50 mIU/ml	[48], 2006
10	146 vaccinated	Iran	birth, 2, 6	47·9%	0	7·5%	95%. After1 booster dose at 10 years if anti-Hbs <50 mIU/ml	[48], 2006
6–11	242 vaccinated	Egypt	3 doses:	39·3%	NT	NT	NT	[44], 2009
6–11	242 vaccinated	Egypt	3, 4, 6	39·3%	NT	NT	NT	[44], 2009
15	663 vaccinated	Canada	3 doses:	76·7%	NT	NT	100%. After 1 booster dose at 15 years if anti-Hbs <10 mIU/ml	[46], 2013
15	663 vaccinated	Canada	birth, 1, 6	76·7%	NT	NT		[46], 2013
15	105 vaccinated	USA (Micronesia)	3 doses:	7·3%	0	7·6%		[37], 2008
15	105 vaccinated	USA (Micronesia)	birth, 2, 6	7·3%	0	7·6%		[37], 2008
17	1704 vaccinated	Italy	3 doses:	84·2%	0	0	NT	[35], 2015
17	1704 vaccinated	Italy	3, 5, 11	84·2%	0	0	NT	[35], 2015
16–18	1355 vaccinated	Saudi Arabia	3 doses:	38%	0	0	NT	[38], 2008
16–18	1355 vaccinated	Saudi Arabia	birth, 1, 5	38%	0	0	NT	[38], 2008
15–17	5981 vaccinated	Taiwan	4 doses:	37%	1·6	4·1	69·7%. After 1 booster dose anti-Hbs <10 mIU/ml	[45], 2008
15–17	5981 vaccinated	Taiwan	birth, 1, 2, 12	37%	1·6	4·1	69·7%. After 1 booster dose anti-Hbs <10 mIU/ml	[45], 2008
18	840 vaccinated	Iran	3 doses:	48·9%	NT	NT	NT	[36], 2014
18	840 vaccinated	Iran	birth, 2, 6	48·9%	NT	NT	NT	[36], 2014
20	1204 non-vaccinated	Taiwan	4 doses: birth, 1, 2, 12	74%	7·4% non-vaccinated 2·2% vaccinated	23·5% non-vaccinated 6·7% vaccinated	NT	[23], 2007
20	6388 vaccinated	Taiwan		74%			NT	[23], 2007
20	300 vaccinated	Iran	3 doses:	37%	0	0	97%. After 1 booster dose at 20 years if anti-Hbs <10 mIU/ml	[49], 2014
20	300 vaccinated	Iran	birth, 2, 6	37%	0	0		[49], 2014
20	843 vaccinated	Taiwan	4 doses:	33·6%	1·4%	2·7%	82·2%. After 1 booster dose at 20 years if anti-Hbs <10 mIU/ml	[22], 2007
20	843 vaccinated	Taiwan	birth, 1, 2, 12	33·6%	1·4%	2·7%		[22], 2007
24	402 vaccinated	China	3 doses:	30·2%	1%	6·7%	84·5%. After1 booster dose at 24 years if anti-Hbs <10 mIU/ml	[39], 2011
24	402 vaccinated	China	birth, 1, 6	30·2%	1%	6·7%		[39], 2011
12–17	719 non-vaccinated	Tunisia	3 doses: 3,4, 6	68·9%	0	1·4% non-vaccinated 0·3% vaccinated	NT	This study
12–17	703 vaccinated	Tunisia		68·9%	0		NT	This study

NT, Not tested.

Anti-HBs titre ⩾10 mIU/ml.

^†

An anamnestic response has defined as a rise within 10–28 days in anti-HBs concentrations to ⩾10 mIU/ml in subjects seronegative for anti-HBs antibodies (or with levels <10 mIU/ml) before challenge dose and as an increase in anti-HBs titres in subjects with seroprotective levels of anti-HBs before challenge.